MariMed (OTC: MRMD) reported quarterly losses of $(0.01) per share which met the analyst consensus estimate. The company reported quarterly sales of $41.925 million which beat the analyst consensus estimate of $39.800 million by 5.34 percent. This is a 5.84 percent increase over sales of $39.611 million the same period last year.